NewAmsterdam Pharma Company N.V.
NAMS58
$17.67arrow_drop_down3.00%-$0.55
High Growth
NAMS58
$17.67
arrow_drop_down3.00%| Key Stats | |
|---|---|
| Open | $18.03 |
| Prev. Close | $18.28 |
| EPS | -2.56 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 17.63 | 19.30 |
| 52 Week Range | 5.63 | 32.34 |
| Ratios | |
|---|---|
| EPS | -2.56 |
| Fundamentals | |
|---|---|
| EBITDA | - |
| Payout Ratio | - |
| Industry average yield | 2.89% |
| Last Dividend pay date | - |
| Dividend per share | - |
| Dividend yield forecast | - |
Stock Analysis
Technicals
Summarizing what the indicators are suggesting.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Analyst rating
An aggregate view of professional's ratings.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Stock Performance
NAMS-
US Healthcare Sector-
US Market-
warning
NAMS / Market
NAMS lose to the US Market which returned 0.03% over the last twenty four hours.warning
NAMS / Healthcare Sector
NAMS lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.NewAmsterdam Pharma Company N.V. (NAMS) Statistics
Keep an eye on NewAmsterdam Pharma Company N.V.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
How has NewAmsterdam Pharma Company N.V. (NAMS) stock's performance compared to its sector and the market over the past year?
Over the past year, NewAmsterdam Pharma Company N.V. (NAMS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, NewAmsterdam Pharma Company N.V. has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights NewAmsterdam Pharma Company N.V.'s performance relative to both its sector and the overall market over the last year.
help
What is the PE ratio of NewAmsterdam Pharma Company N.V. (NAMS) stock?
The PE ratio for NewAmsterdam Pharma Company N.V. (NAMS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help
What is the EPS of NewAmsterdam Pharma Company N.V. (NAMS) stock?
The Earnings Per Share (EPS) for NewAmsterdam Pharma Company N.V. (NAMS), calculated on a diluted basis, is -$2.56. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help
What is the operating margin of NewAmsterdam Pharma Company N.V. (NAMS) stock?
The operating margin for NewAmsterdam Pharma Company N.V. (NAMS) is -338.47%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help
What is the EBITDA of NewAmsterdam Pharma Company N.V. (NAMS) stock?
Currently, the EBITDA information for NewAmsterdam Pharma Company N.V. (NAMS) is not available. This might be due to various reasons such as the company not disclosing this information for the period in question or recent updates not being reflected.
help
How much debt does NewAmsterdam Pharma Company N.V. (NAMS) have?
NewAmsterdam Pharma Company N.V. (NAMS) has a total debt of $448K. The net debt, which accounts for cash and cash equivalents against the total debt, is -$771.3M.